Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The expansion makes Exothera one of the largest viral vector facilities in Europe
Successful proposals will secure fully funded postdoctoral research positions
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Collaboration in the industry needs to be institutionalised to drive the growth.
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
It is being developed by Pune-based Gennova Biopharmaceuticals
Subscribe To Our Newsletter & Stay Updated
